摘要
结肠癌是一种常见的消化系统恶性肿瘤,鼠肉瘤病毒致癌基因(kirsten rat sarcoma viral oncogene,KRAS)突变率高,预后较差,本文报道2017年9月首都医科大学附属北京朝阳医院肿瘤科收治的1例经FOLFIRI方案(亚叶酸钙+5-氟尿嘧啶+依立替康)、卡培他滨、贝伐珠单抗+雷替曲塞等多线治疗疾病进展后,接受基于瑞戈非尼的多线治疗后依旧生存的KRAS突变右半结肠癌病例。目前患者总生存时间为46个月,提示患者可以从持续抗血管生成治疗中获益,为临床治疗KRAS突变右半结肠癌提供新思路。
Colon cancer is a most common digestive system tumor,with high kirsten rat sarcoma viral oncogene(KRAS)mutation rate and poor prognosis.This article reports a case of right-side colon cancer with KRAS mutation,which was admitted and treated in the Department of Oncology,Beijing Chao-Yang Hospital in September 2017.The disease progressed after multiline therapy of FOLFIRI regimen(calcium folinate+5-fluorouracil+irinotecan),capecitabine,bevacizumab and raltitrexed.However,the patient survived from multiline therapy based on regorafenib.The overall survival time is 46 months.This case indicates that patient can benefit from continuous anti-angiogenic therapy,and provides a new idea for clinical treatment of right-side colon cancer with KRAS mutation.
作者
梁紫葳
姚健楠
安广宇
葛洋
Liang Ziwei;Yao Jiannan;An Guangyu;Ge Yang(Department of Oncology,Beijing Chao-Yang Hospital,Capital Medical University,Beijing 100020,China)
出处
《肿瘤综合治疗电子杂志》
2021年第3期55-59,共5页
Journal of Multidisciplinary Cancer Management(Electronic Version)